yingweiwo

ALG-055009

ALG-055009 is a thyroid hormone receptor β (THR-β) agonist with an EC50 value of 0.063 μM.
ALG-055009
ALG-055009 Chemical Structure CAS No.: 2542029-03-6
Product category: Thyroid Hormone Receptor
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
1mg
Other Sizes
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text

 

  • Business Relationship with 5000+ Clients Globally
  • Major Universities, Research Institutions, Biotech & Pharma
  • Citations by Top Journals: Nature, Cell, Science, etc.
Top Publications Citing lnvivochem Products
Product Description
ALG-055009 is a thyroid hormone receptor β (THR-β) agonist with an EC50 value of 0.063 μM. ALG-055009 can reduce total cholesterol levels in rats fed a high-fat diet. ALG-055009 can be used to study fatty liver disease associated with metabolic dysfunction.
ALG-055009 is a potent and selective agonist of the thyroid hormone receptor beta (THR-beta), with a molecular formula of C16H14Cl2N6O4 and a molecular weight of 425.23 g/mol. Its chemical name is 6-Amino-2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-1,2,4-triazine-3,5(2H,4H)-dione. It is an orally available research compound in development for treating MASH (Metabolic Dysfunction-Associated Steatohepatitis) and for reducing serum lipids.
Biological Activity I Assay Protocols (From Reference)
Targets
ALG-055009 is a potent and selective agonist of the thyroid hormone receptor beta (THR-beta). It exhibits an EC50 of 63 nM (0.063 microM) and is 5.7-fold selective over the THR-alpha subtype. By activating THR-beta, it mimics the lipid-lowering effects of thyroid hormones in the liver while avoiding the cardiac side effects associated with THR-alpha activation.
ln Vitro
ALG-055009 is a potent THR-beta agonist with an EC50 of 63 nM in vitro. This activity is likely measured in a cell-based luciferase reporter assay where THR-beta activation drives expression of a luminescent reporter gene. Its 5.7-fold selectivity for THR-beta over THR-alpha is a key feature that reduces the risk of cardiotoxicity.
ln Vivo
In vivo, ALG-055009 has shown efficacy in a high-fat diet rat model. At doses greater than 0.075 mg/kg, it reduces serum lipid levels. It also significantly increases hepatic gene expression of Dio1 and Me1, which are markers of THR-beta activation, at doses of 0.15 and 0.5 mg/kg. This data supports its development for treating dyslipidemia and MASH.
Enzyme Assay
THR-beta agonist activity is typically measured using a cell-based reporter gene assay, not a cell-free binding assay. However, to measure binding affinity, a competitive binding assay using radiolabeled triiodothyronine (T3) and purified THR-beta ligand-binding domain (LBD) can be used. Procedure: The THR-beta LBD is incubated with 0.1 nM [125I]-T3 and varying concentrations of ALG-055009 (0.01 nM to 10 microM) in binding buffer for 4 hours at 4degC. Free radioligand is separated using a spin column or charcoal-dextran method. Bound radioactivity is counted in a gamma counter. The IC50 is calculated, and the Ki is derived using the Cheng-Prusoff equation.
Cell Assay
The functional potency of ALG-055009 is assessed in a THR-beta reporter cell line. Procedure: HEK-293 cells are transiently or stably transfected with a plasmid encoding human THR-beta and a luciferase reporter gene under the control of a thyroid hormone response element (TRE). Cells are seeded in 96-well white plates (20,000 cells/well) and incubated for 24 hours. The medium is replaced with medium containing varying concentrations of ALG-055009 (0.01 nM to 10 microM) and incubated for 24 hours. The cells are then lysed, and luciferase activity is measured by adding a luciferin substrate and reading luminescence in a plate reader. The EC50 is calculated as the concentration that produces 50% of the maximal T3 response.
Animal Protocol
The in vivo efficacy of ALG-055009 is evaluated in a high-fat diet (HFD)-induced hyperlipidemia rat model. Procedure: Male Sprague-Dawley rats are fed a HFD (60% kcal from fat) for 4 weeks to induce hyperlipidemia. The rats are then randomized into treatment groups (n=8). ALG-055009 is formulated in a vehicle (e.g., 0.5% methylcellulose) and administered orally once daily at doses of 0.01, 0.05, 0.1, and 0.5 mg/kg for 14 days. Blood samples are collected on days 0, 7, and 14 for lipid panel analysis (total cholesterol, triglycerides, LDL-C, HDL-C). At the end of the study, liver tissue is collected for qRT-PCR analysis of THR-beta target genes, including Dio1 and Me1.
ADME/Pharmacokinetics
ALG-055009 is orally bioavailable and active in rats. Pharmacokinetic parameters have not been detailed in the search results, but as an orally active compound being developed for MASH, it is expected to have favorable absorption and a half-life suitable for once-daily dosing. The molecular weight is 425.23, and it likely has high passive permeability due to its lipophilic nature. It is expected to have extensive first-pass metabolism in the liver, which is typical for thyroid hormone agonists.
Toxicity/Toxicokinetics
Specific toxicity data for ALG-055009 is not provided. As a selective THR-beta agonist, the primary safety concern is potential off-target activation of THR-alpha in the heart, which can cause tachycardia and arrhythmias. Its 5.7-fold selectivity is designed to mitigate this risk. However, no long-term toxicology studies in higher species have been reported in the search results. It is an investigational compound, and standard safety pharmacology (including hERG) and toxicology studies are likely ongoing.
References

[1]. Discovery and Preclinical Profile of ALG-055009, a Potent and Selective Thyroid Hormone Receptor Beta (THR-β) Agonist for the Treatment of MASH. J Med Chem. 2024 Sep 12;67(17):14840-14851.

Additional Infomation
ALG-055009 is an investigational drug being developed for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease, and hyperlipidemia. The selective activation of THR-beta has emerged as a promising therapeutic strategy because it promotes the clearance of lipids from the liver without causing the cardiac strain associated with non-selective thyroid hormone mimetics. This compound represents a next-generation thyroid hormone mimetic that offers a potentially safer profile than earlier non-selective compounds. This product is for research use only and is not an FDA-approved drug.
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C16H14CL2N6O4
Molecular Weight
425.23
CAS #
2542029-03-6
Appearance
Off-white to light yellow solid
SMILES
CC(C1=CC(OC2=C(Cl)C=C(N3N=C(C(NC3=O)=O)N)C=C2Cl)=NNC1=O)C
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO: ~50 mg/mL (~117.6 mM; with ultrasonication)
Solubility (In Vivo)
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.88 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 2: ≥ 2.5 mg/mL (5.88 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 2.3517 mL 11.7583 mL 23.5167 mL
5 mM 0.4703 mL 2.3517 mL 4.7033 mL
10 mM 0.2352 mL 1.1758 mL 2.3517 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration: mg/mL;

Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Contact Us